BDBM620289 (2R,3R,4S,5R,6R)-6-((1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)methyl)-4-(4-(3,5- difluoro-4-methylphenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)-5- methoxytetrahydro-2H-pyran-3-ol::US20230295182, Example 1.21

SMILES CO[C@H]1[C@@H](CC2=NOC3(C2)CCCCC3)O[C@H](CO)[C@H](O)[C@@H]1n1cc(nn1)-c1cc(F)c(C)c(F)c1

InChI Key InChIKey=FCTMTYDSWDSLAU-UHFFFAOYSA-N

Data  2 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 620289   

TargetGalectin-3(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620289(US20230295182, Example 1.21 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetGalectin-1(Human)
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620289(US20230295182, Example 1.21 | (2R,3R,4S,5R,6R)-6-(...)
Affinity DataIC50: 1.14E+4nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent